EAPI Euroapi S.A.
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Euroapi (EPA: EAPI)
›
Euroapi (EPA: EAPI) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 3,000 employees.
The shares were at 0.6820 EUR on 19 November 2026, down 78.2% over 52 weeks. Its 52-week range is 0.6610 EUR to 3.282 EUR: the price is 79.2% below the high and 3.2% above the low.
Its market capitalisation is 65.15M EUR.
Euroapi reports return on equity of -26.8%, an operating margin of -2.5% and revenue down 14.0% year over year.
Its debt exceeds its cash by 57.00M EUR, a debt-to-equity ratio of 0.08. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 1.000 EUR is 46.6% above the current price. The next earnings report is expected on 3 March 2027.